These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23977976)

  • 21. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?
    Gold R; Toumi M; Meesen B; Fogarty E
    Mult Scler; 2016 Aug; 22(2 Suppl):60-70. PubMed ID: 27465616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Jurisdictions on the reimbursement of new medical technologies by public health insurance: A systematic review].
    Ex P; Felgner S; Henschke C
    Z Evid Fortbild Qual Gesundhwes; 2018 Apr; 131-132():8-16. PubMed ID: 29331280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
    Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
    Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the economic downturn on healthcare in Spain: consequences and alternatives.
    Antonanzas F
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):433-9. PubMed ID: 23977971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reimbursing new technologies: why are the courts judging experimental medicine?
    Saver RS
    Stanford Law Rev; 1992 May; 44(5):1095-131. PubMed ID: 10119850
    [No Abstract]   [Full Text] [Related]  

  • 27. Federal Medicaid policy. Year end issue brief.
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-50. PubMed ID: 18345579
    [No Abstract]   [Full Text] [Related]  

  • 28. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing outside the limits of marketing authorizations and reimbursement by the French universal health insurance system.
    Avouac B
    Joint Bone Spine; 2002 Dec; 69(6):534-7. PubMed ID: 12537259
    [No Abstract]   [Full Text] [Related]  

  • 30. The medical device payment controversy rages on.
    Brown E
    Physician Exec; 1995 Nov; 21(11):40-1. PubMed ID: 10153735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new era for cardiovascular imaging? Implications of the revoked national coverage decision for CT angiography on future imaging reimbursement.
    Douglas PS; Budoff M; Tunis S; Woodard PK; Justman RA; Honigberg R
    JACC Cardiovasc Imaging; 2008 May; 1(3):398-403. PubMed ID: 19356455
    [No Abstract]   [Full Text] [Related]  

  • 32. [Development costs, regulation and audit in the German SHI Drug Sector].
    Kamp F; Walter P; Bücheler R
    Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
    [No Abstract]   [Full Text] [Related]  

  • 33. Legal and policy aspects of home care coverage.
    Weitzman SM
    Ann Health Law; 1992; 1():1-35. PubMed ID: 10141598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation on the first 2 years of the positive list system in South Korea.
    Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
    Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving health-care regulations in China.
    Ouyang Y
    Lancet Oncol; 2017 Jun; 18(6):714. PubMed ID: 28528748
    [No Abstract]   [Full Text] [Related]  

  • 37. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 21st Century Cures Act and Early Feasibility Studies for Cardiovascular Devices: What Have We Learned, Where Do We Need to Go?
    Holmes DR; Hance R; Syrek Jensen TS; Schwartz DA; Kaplan A; Farb A; Zuckerman B; Leon M; Waklowiak J; Mack MJ; Shuren J
    JACC Cardiovasc Interv; 2018 Nov; 11(21):2220-2225. PubMed ID: 30409280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
    Fisfis BA
    Spec Law Dig Health Care Law; 1994 Mar; (181):9-32. PubMed ID: 10133063
    [No Abstract]   [Full Text] [Related]  

  • 40. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.